[CVM] Cel-Sci Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 0.08 Change: -0.01 (-13.39%)
Ext. hours: 0.08 Change: 0 (0%)

chart CVM

Refresh chart

Strongest Trends Summary For CVM

CVM is in the medium-term down -30% below S&P in 8 months. In the long-term up 126% in 2 years and up 1468% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: CEL-SCI Corporation is engaged in the research and development of drugs and vaccines. The company?s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. In addition, it is developing Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, is developing a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 1137.5% Sales Growth - Q/Q44.53% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-236.26% ROE-8765.89% ROI-337.3%
Current Ratio1.55 Quick Ratio1.12 Long Term Debt/Equity4.25 Debt Ratio10.73
Gross Margin Operating Margin-7915.99% Net Profit Margin-7175.9% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities6.4 M Cash From Investing Activities-60 K Cash From Operating Activities-12.24 M Gross Profit
Net Profit-12.56 M Operating Profit-7.76 M Total Assets12.73 M Total Current Assets5.7 M
Total Current Liabilities3.68 M Total Debt1.12 M Total Liabilities12.38 M Total Revenue200 K
Technical Data
High 52 week9.6 Low 52 week2.58 Last close8.36 Last change5.96%
RSI43.4 Average true range0.67 Beta0.61 Volume4.05 M
Simple moving average 20 days-3.58% Simple moving average 50 days1.55% Simple moving average 200 days45.21%
Performance Data
Performance Week1.46% Performance Month-8.33% Performance Quart31.45% Performance Half40.5%
Performance Year121.75% Performance Year-to-date191.29% Volatility daily4.28% Volatility weekly9.57%
Volatility monthly19.61% Volatility yearly67.93% Relative Volume100.03% Average Volume690.4 K
New High New Low-15.44%

News

2020-05-28 13:07:00 | CVM: Last Event Completed; On To Analysis

2020-05-11 08:00:00 | CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results

2020-05-08 06:20:00 | CVM: 298 Events Achieved

2020-05-04 07:15:00 | CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of Head and Neck Cancer

2020-04-23 09:15:00 | CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

2020-04-08 08:00:00 | Important Update For CEL-SCI Corporation Annual Meeting of Shareholders

2020-03-30 16:05:00 | CEL-SCI Announces Change of Location to 2020 Annual Meeting of Shareholders

2020-03-26 11:05:00 | CEL-SCI Announces the Closing of Its $7.7 Million Bought Deal

2020-03-24 09:25:00 | CEL-SCI Increases Previously Announced Bought Deal to $7.7 Million

2020-03-23 21:46:00 | CEL-SCI Announces Bought Deal Offering

2020-03-23 09:00:00 | CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center for Vaccines and Immunology

2020-03-10 12:00:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CEL-SCI Corporation - CVM

2020-03-09 07:55:00 | CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection

2020-02-27 12:44:10 | Oil stocks continue losing streak amid coronavirus fears

2020-02-27 04:10:00 | CVM: Rumor and Pandemic: A Volatile Mix They Make

2020-02-26 15:19:00 | CEL-SCI Corporation Issues Letter to Shareholders

2020-02-10 08:00:00 | CEL-SCI Corporation Reports First Quarter Fiscal 2020 Financial Results

2020-02-06 09:00:00 | CEL-SCI to Present at 2020 BIO CEO & Investor Conference

2020-01-10 08:30:00 | CEL-SCI to Participate in Upcoming Investor Conferences

2020-01-07 14:40:00 | CEL-SCI Announces Full Exercise of Over-allotment Option by Aegis Capital Corp.

2019-12-27 11:15:00 | CEL-SCI Announces the Closing of Its $5.5 Million Underwritten Offering

2019-12-26 09:59:02 | Company News For Dec 26, 2019

2019-12-24 07:16:00 | CEL-SCI Prices $5.5 Million Underwritten Public Offering of Common Stock

2019-12-23 16:04:00 | CEL-SCI Announces Proposed Underwritten Public Offering of Common Stock

2019-12-20 15:28:09 | Hedge Funds Are Buying CEL-SCI Corporation CVM

2019-12-16 16:15:00 | CEL-SCI Reports Fiscal 2019 Financial Results and Clinical & Corporate Developments

2019-12-06 09:00:00 | CEL-SCI Corporation to Present at The LD Micro Main Event XII

2019-10-29 07:00:00 | CEL-SCI Corporation to Present at Dawson James Securities 5th Annual Small Cap Growth Conference

2019-10-24 09:00:00 | CEL-SCI Corporation Issues Letter to Shareholders

2019-10-16 19:30:00 | CVM: IDMC Nod & Target Price Raise

2019-10-15 08:30:00 | CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

2019-09-25 11:35:00 | CVM: A Focus on LEAPS

2019-09-04 12:14:00 | CEL-SCI Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

2019-08-14 16:20:00 | CEL-SCI Corporation Reports Third Quarter Fiscal 2019 Financial Results

2019-07-23 09:30:00 | CEL-SCI’s Scientific Review on Inflammatory Disease Therapies Published in Peer Reviewed Journal “International Immunopharmacology”

2019-07-08 09:00:00 | CEL-SCI Collaborators Presents Data for New Vaccine in the Treatment of Rheumatoid Arthritis at the International Conference on Immunity and Immunochemistry Meeting

2019-06-23 09:00:00 | These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

2019-06-19 10:30:00 | CVM: No Free Samples on Facility Tour

2019-06-11 16:35:28 | The Companies Set To Join The Russell Index July 1

2019-06-10 09:00:00 | CEL-SCI Corporation Set to Join Russell 3000® Index

2019-06-03 09:00:00 | CEL-SCI Corporation to Present at the 9th Annual LD Micro Invitational

2019-05-29 13:00:00 | CVM: Second Quarter 2019 Results

2019-05-14 16:33:16 | Cel-Sci: Fiscal 2Q Earnings Snapshot

2019-05-14 16:20:00 | CEL-SCI Corporation Reports Second Quarter Fiscal 2019 Financial Results

2019-05-13 09:00:00 | CEL-SCI Presents New Data for Its LEAPS Vaccine in the Treatment of Rheumatoid Arthritis at the American Association of Immunologists 103rd Annual Meeting

2019-05-08 08:00:00 | CEL-SCI Corporation Releases Letter to Shareholders

2019-04-30 09:00:00 | CEL-SCI to Present at the ThinkEquity Conference

2019-03-29 09:00:00 | CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

2019-03-26 18:16:05 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CEL-SCI Corporation

2019-03-25 08:12:00 | CEL-SCI Corporation Releases Letter to Shareholders